Skip to main content
Log in

Biologic Therapy for Rheumatoid Arthritis

Clinical Efficacy and Predictors of Response

  • Therapy Review
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Rheumatoid arthritis (RA) is a chronic, disabling disease of the synovial joints, thought to be autoimmune in origin. The emergence of biologic therapies has proven to be highly successful in effectively treating RA in the majority of cases. However, the cost of these agents is high and some patients do not respond to these drugs, or they suffer from adverse events. This article will review the currently available data on efficacy and the clinical, genetic, and biomarkers of response to these biologic therapies in RA.

The anti-tumour necrosis factor-alpha (anti-TNFα) agents, adalimumab, etanercept and infliximab, act to neutralize the pro-inflammatory cytokine. Response to these agents is higher in patients receiving concurrent disease modifying anti-rheumatic drugs or non-steroidal anti-inflammatory drugs, in those with lesser disability, and in non-smokers. Many genetic predictors of response have been investigated, such as the shared epitope, the TNF gene and its receptors, but none have been absolutely confirmed. Synovial expression of TNFα has been suggested as a biomarker of response, while anti-cyclic citrullinated peptide antibody and rheumatoid factor (RF)-positivity predict poor response. Newer biologic agents include the interleukin (IL)-1 receptor antagonist anakinra, the B-cell depleting agent rituximab, the selective costimulation modulator abatacept, and the anti-IL-6 receptor monoclonal antibody tocilizumab. No genetic studies of response to these agents have been performed to date. However, it has been reported that low synovial infiltration of B cells and complete B-cell depletion after the first rituximab infusion are predictors of good response to this agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Klareskog L, Van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004 Feb 28; 363(9410): 675–81

    Article  PubMed  CAS  Google Scholar 

  2. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000 Nov 30; 343(22): 1586–93

    Article  PubMed  CAS  Google Scholar 

  3. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006 Jan; 54(1): 26–37

    Article  PubMed  CAS  Google Scholar 

  4. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004 Nov; 50(11): 3432–43

    Article  PubMed  CAS  Google Scholar 

  5. O’Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004 Jun 17; 350(25): 2591–602

    Article  PubMed  Google Scholar 

  6. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001 Mar 22; 344(12): 907–16

    Article  PubMed  CAS  Google Scholar 

  7. Feldmann M, Maini RN. Discovery of TNF-α as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine 2002; 69(1): 12–8

    Article  PubMed  Google Scholar 

  8. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999 Mar 16; 130(6): 478–86

    PubMed  CAS  Google Scholar 

  9. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003 Jan; 48(1): 35–45

    Article  PubMed  CAS  Google Scholar 

  10. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999 Jan 28; 340(4): 253–9

    Article  PubMed  CAS  Google Scholar 

  11. Lipsky PE, Van der Heijde DMFM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343(22): 1594–602

    Article  PubMed  CAS  Google Scholar 

  12. Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007 Jul; 46(7): 1140–7

    Article  PubMed  CAS  Google Scholar 

  13. Hochberg MC, Tracy JK, Hawkins-Holt M, et al. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003 Nov; 62Suppl. 2: ii13–16

    PubMed  CAS  Google Scholar 

  14. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006 Nov; 10 (42): iii–iv, xi–xiii, 1-229

  15. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995 Jun; 38(6): 727–35

    Article  PubMed  CAS  Google Scholar 

  16. Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2008 Feb; 58(2 Suppl.): S126–35

    PubMed  CAS  Google Scholar 

  17. Van der Bijl AE, Goekoop-Ruiterman YP, De Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2007 Jul; 56(7): 2129–34

    Article  PubMed  Google Scholar 

  18. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005 Feb; 44(2): 157–63

    Article  PubMed  CAS  Google Scholar 

  19. Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006 Nov; 54(11): 3399–407

    Article  PubMed  CAS  Google Scholar 

  20. Kievit W, Fransen J, Oerlemans AJ, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 2007 Nov; 66(11): 1473–8

    Article  PubMed  CAS  Google Scholar 

  21. Greenberg JD, Kishimoto M, Strand V, et al. Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort. Am J Med 2008 Jun; 121(6): 532–8

    Article  PubMed  CAS  Google Scholar 

  22. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006; 8(1): R29

    Article  PubMed  Google Scholar 

  23. Zink A, Joachim L, Kary S, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005; 64: 1274–9

    Article  PubMed  CAS  Google Scholar 

  24. Kristensen LE, Saxne T, Nilsson JA, et al. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis: results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006; 8(6): R174

    Article  PubMed  Google Scholar 

  25. Hyrich KL, Watson KD, Silman AJ, et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006 Dec; 45(12): 1558–65

    Article  CAS  Google Scholar 

  26. Hyrich KL, Symmons DP, Watson KD, et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006 Jun; 54(6): 1786–94

    Article  PubMed  CAS  Google Scholar 

  27. Finckh A, Dehler S, Gabay C. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis 2009 Jan; 68 (1): 33-9

    Google Scholar 

  28. Kristensen LE, Kapetanovic MC, Gulfe A, et al. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008 Apr; 47(4): 495–9

    Article  PubMed  CAS  Google Scholar 

  29. Radovits BJ, Kievit W, Fransen J, et al. Influence of age on the outcome of anti-TNFalphatherapy in rheumatoid arthritis. Ann Rheum Dis Epub 2008 Nov 19

  30. Fernandez-Nebro A, Irigoyen MV, Urena I, et al. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. J Rheumatol 2007 Dec; 34(12): 2334–42

    PubMed  CAS  Google Scholar 

  31. Geborek P, Crnkic M, Petersson IF, et al. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61(9): 793–8

    Article  PubMed  CAS  Google Scholar 

  32. Fitzcharles M-A, Clayton D, Menard HA. The use of infliximab in academic rheumatology practice: an audit of early clinical experience. J Rheumatol 2002; 29(12): 2525–30

    PubMed  CAS  Google Scholar 

  33. Scott DL, Steer S. The course of established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007 Oct; 21(5): 943–67

    Article  PubMed  Google Scholar 

  34. van Zeben D, Breedveld FC. Prognostic factors in rheumatoid arthritis. J Rheumatol Suppl 1996 Mar; 44: 31–3

    PubMed  Google Scholar 

  35. Anderson JJ, Wells G, Verhoeven AC, et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000 Jan; 43(1): 22–9

    Article  PubMed  CAS  Google Scholar 

  36. Martinez A, Salido M, Bonilla G, et al. Association of the major histo-compatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 2004 Apr; 50(4): 1077–82

    Article  PubMed  CAS  Google Scholar 

  37. Criswell LA, Lum RF, Turner KN, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004 Sep; 50(9): 2750–6

    Article  PubMed  CAS  Google Scholar 

  38. Kang CP, Lee KW, Yoo DH, et al. The influence of a polymorphism at position −857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford) 2005 Apr; 44(4): 547–52

    Article  CAS  Google Scholar 

  39. Marotte H, Pallot-Prades B, Grange L, et al. The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis 2006 Mar; 65(3): 342–7

    Article  PubMed  CAS  Google Scholar 

  40. Miceli-Richard C, Comets E, Verstuyft C, et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis 2008 Apr; 67(4): 478–84

    Article  PubMed  CAS  Google Scholar 

  41. Potter C, Hyrich KL, Tracey A, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 2009 Jan; 68(1): 69–74

    Article  PubMed  CAS  Google Scholar 

  42. Mugnier B, Balandraud N, Darque A, et al. Polymorphism at position −308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003 Jul; 48(7): 1849–52

    Article  PubMed  CAS  Google Scholar 

  43. Padyukov L, Lampa J, Heimburger M, et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003 Jun; 62(6): 526–9

    Article  PubMed  CAS  Google Scholar 

  44. Cuchacovich M, Soto L, Edwardes M, et al. Tumour necrosis factor (TNF)alpha −308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol 2006 Nov; 35(6): 435–40

    Article  PubMed  CAS  Google Scholar 

  45. Lee YH, Rho YH, Choi SJ, et al. Association of TNF-alpha −308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 2006 Dec; 27(2): 157–61

    Article  PubMed  CAS  Google Scholar 

  46. Seitz M, Wirthmuller U, Moller B, et al. The −308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2007 Jan; 46(1): 93–6

    Article  CAS  Google Scholar 

  47. Guis S, Balandraud N, Bouvenot J, et al. Influence of −308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum 2007 Dec 15; 57(8): 1426–30

    Article  PubMed  Google Scholar 

  48. Marotte H, Arnaud B, Diasparra J, et al. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at −308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 2008 May; 58(5): 1258–63

    Article  PubMed  CAS  Google Scholar 

  49. Maxwell JR, Potter C, Hyrich KL, et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008 Nov 15; 17(22): 3532–8

    Article  PubMed  CAS  Google Scholar 

  50. Fabris M, Tolusso B, Di Poi E, et al. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J Rheumatol 2002 Sep; 29(9): 1847–50

    PubMed  CAS  Google Scholar 

  51. Rooryck C, Barnetche T, Richez C, et al. Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy. Clin Exp Rheumatol 2008 Mar; 26(2): 340–2

    PubMed  CAS  Google Scholar 

  52. Toonen EJ, Coenen MJ, Kievit W, et al. The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Ann Rheum Dis 2008 Aug; 67(8): 1174–7

    Article  PubMed  CAS  Google Scholar 

  53. Kastbom A, Bratt J, Ernestam S, et al. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum 2007 Feb; 56(2): 448–52

    Article  PubMed  CAS  Google Scholar 

  54. Schotte H, Schluter B, Drynda S, et al. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis 2005 Apr; 64(4): 575–81

    Article  PubMed  CAS  Google Scholar 

  55. Radstake TR, Fransen J, Toonen EJ, et al. Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritis. Ann Rheum Dis 2007 Nov; 66(11): 1525–30

    Article  PubMed  CAS  Google Scholar 

  56. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987 Nov; 30(11): 1205–13

    Article  PubMed  CAS  Google Scholar 

  57. Chatzikyriakidou A, Georgiou I, Voulgari PV, et al. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients’ response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. Rheumatology (Oxford) 2007 Jun; 46(6): 1034–5

    Article  CAS  Google Scholar 

  58. Hinks A, Barton A, John S, et al. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum 2005 Jun; 52(6): 1694–9

    Article  PubMed  CAS  Google Scholar 

  59. Tutuncu Z, Kavanaugh A, Zvaifler N, et al. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005 Sep; 52(9): 2693–6

    Article  PubMed  CAS  Google Scholar 

  60. Wijbrandts CA, Dijkgraaf MG, Kraan MC, et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis 2008 Aug; 67(8): 1139–44

    Article  PubMed  CAS  Google Scholar 

  61. Fabre S, Dupuy AM, Dossat N, et al. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol 2008 Aug; 153(2): 188–95

    Article  PubMed  CAS  Google Scholar 

  62. Pachot A, Arnaud B, Marrote H, et al. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response. J Rheumatol 2007 Nov; 34(11): 2158–61

    PubMed  CAS  Google Scholar 

  63. Buch MH, Reece RJ, Quinn MA, et al. The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). Rheumatology (Oxford) 2008 Oct; 47(10): 1469–75

    Article  CAS  Google Scholar 

  64. Marotte H, Maslinski W, Miossec P. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther 2005; 7(1): R149–55

    Article  PubMed  CAS  Google Scholar 

  65. Braun-Moscovici Y, Markovits D, Zinder O, et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 2006 Mar; 33(3): 497–500

    PubMed  CAS  Google Scholar 

  66. Morozzi G, Fabbroni M, Bellisai F, et al. Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis. Clin Rheumatol 2007 Aug; 26(8): 1335–8

    Article  PubMed  CAS  Google Scholar 

  67. Gonzalez-Alvaro I, Ortiz AM, Tomero EG, et al. Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann Rheum Dis 2007 Dec; 66(12): 1675–8

    Article  PubMed  CAS  Google Scholar 

  68. Lequerre T, Jouen F, Brazier M, et al. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology (Oxford) 2007 Mar; 46(3): 446–53

    Article  CAS  Google Scholar 

  69. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002 Mar; 46(3): 614–24

    Article  PubMed  CAS  Google Scholar 

  70. Cohen SB, Strand V, Aguilar D, et al. Patient-versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy. Rheumatology (Oxford) 2004 Jun; 43(6): 704–11

    Article  CAS  Google Scholar 

  71. Konttinen L, Kankaanpaa E, Luosujarvi R, et al. Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study. Clin Rheumatol 2006 Nov; 25(6): 882–4

    Article  PubMed  Google Scholar 

  72. Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. J Rheumatol 2006 Dec; 33(12): 2398–408

    PubMed  CAS  Google Scholar 

  73. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004 May; 50(5): 1412–9

    Article  PubMed  CAS  Google Scholar 

  74. National Institute for Clinical Excellence. The management of adults with rheumatoid arthritis [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/CG79NICEGuideline.pdf [Accessed 2009 Apr 14]

  75. Kalliolias GD, Liossis SN. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still’s disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 2008 Mar; 17(3): 349–59

    Article  PubMed  CAS  Google Scholar 

  76. Dass S, Vital EM, Emery P. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2006 Dec; 7(18): 2559–70

    Article  PubMed  CAS  Google Scholar 

  77. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med 2008 Aug 7; 359(6): 613–26

    Article  PubMed  CAS  Google Scholar 

  78. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006 May; 54(5): 1390–400

    Article  PubMed  CAS  Google Scholar 

  79. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006 Sep; 54(9): 2793–806

    Article  PubMed  CAS  Google Scholar 

  80. Rituxan (rituximab) injection for intravenous use: highlights of US prescribing information [online]. Available from URL: http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf [Accessed 2009 Apr 17]

  81. Leandro MJ, Cambridge G, Ehrenstein MR, et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006 Feb; 54(2): 613–20

    Article  PubMed  CAS  Google Scholar 

  82. Teng YK, Levarht EW, Hashemi M, et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007 Dec; 56(12): 3909–18

    Article  PubMed  CAS  Google Scholar 

  83. Dass S, Rawstron AC, Vital EM, et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008 Oct; 58(10): 2993–9

    Article  PubMed  CAS  Google Scholar 

  84. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006 Jun 20; 144(12): 865–76

    PubMed  CAS  Google Scholar 

  85. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005 Sep 15; 353(11): 1114–23

    Article  PubMed  CAS  Google Scholar 

  86. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008 Aug; 67(8): 1096–103

    Article  PubMed  CAS  Google Scholar 

  87. Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007 Feb; 66(2): 228–34

    Article  PubMed  CAS  Google Scholar 

  88. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006 Sep; 54(9): 2817–29

    Article  PubMed  CAS  Google Scholar 

  89. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008 Mar 22; 371(9617): 987–97

    Article  PubMed  CAS  Google Scholar 

  90. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008 Nov; 67(11): 1516–23

    Article  PubMed  CAS  Google Scholar 

  91. RoActemra: European public assessment report [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/RoActemra/RoActemra.htm [Accessed 2009 Apr 17]

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this review. The authors declare no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gibbons, L.J., Hyrich, K.L. Biologic Therapy for Rheumatoid Arthritis. BioDrugs 23, 111–124 (2009). https://doi.org/10.2165/00063030-200923020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200923020-00004

Keywords

Navigation